Interleukin-37 expression is decreased in Behçet's disease and is associated with inflammation

Immunology Letters

Volumn 167, Issue 2, 2015, Pages 87-94

  Bouali, Eya ^a   Kaabachi, Wajih ^a   Hamzaoui, Agnes ^a   Hamzaoui, Kamel ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Beh et disease; IL 17; IL 1 ; IL 6; Interleukin 37; TNF

Indexed keywords

CORTICOSTEROID; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 37; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUPERNATANT; BEHCET SYNDROME; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL;

ADULT; BEHCET SYNDROME; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 84939421133     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.08.001     Document Type: Article

References (36)

1. Sugita S., Kawazoe Y., Imai A., Kawaguchi T., Horie S., Keino H., et al. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease. J. Immunol. 2013, 190(11):5799-5808.
2. Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet's disease. Autoimmun. Rev. 2012, 11(10):699-704.
3. Hamzaoui K., Bouali E., Ghorbel I., Khanfir M., Houman H., Hamzaoui A. Expression of Th-17 and RORγt mRNA in Behçet's disease. Med. Sci. Monit. 2011, 17(4):CR227-34.
4. Hamzaoui K., BorhaniHaghighi A., Ghorbel I.B., Houman H. RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet's disease. J. Neuroimmunol. 2011, 233(1-2):249-253.
5. Hamzaoui K., Hamzaoui A., Guemira F., Bessioud M., Hamza M., Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand. J. Rheumatol. 2002, 31(4):205-210.
6. Melikoglu M., Uysal S., Krueger J.G., Kaplan G., Gogus F., Yazici H., et al. Characterization of the divergent wound healing responses occurring in the pathergy reaction and normal healthy volunteers. J. Immunol. 2006, 177:6415-6421.
7. Shimizu J., Takai K., Takada E., Fujiwara N., Arimitsu N., Ueda Y., et al. Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet's disease. Clin. Rheumatol. 2015.
8. Manzanillo P., Eidenschenk C., Ouyang W. Deciphering the crosstalk among IL-1 and IL-10 family cytokines in intestinal immunity. Trends Immunol. 2015, S1471-S4906. pii: S1471-4906(15)00150 -7.
9. Busfield S.J., Comrack C.A., Yu G., Chickering T.W., Smutko J.S., Zhou H., et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 2000, 66:213-216.
10. Pan G., Risser P., Mao W., Baldwin D.T., Zhong A.W., Filvaroff E., et al. IL-1H, an interleukin-1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001, 13:1-7.
11. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010, 11:1014. 22.
12. Liang Y., Ling J., Zhongyang W., Yanfei Z., Dongsheng H., Yanqun L., et al. IL-37 inhibits the production of inflammatory cytokines in peripheral bloodmononuclear cells of patients with systemic lupus erythematosus, its correlation with disease activity. J. Transl. Med. 2014, 12:69. 10.1186/1479-5876-12-69.
13. Zhao P.W., Jiang W.G., Wang L., Jiang Z.Y., Shan Y.X., Jiang Y.F. Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One 2014, 9(5):e95346.
14. Song L.J., Qiu F., Fan Y.C., Ding F., Liu H.X., Shu Q., et al. Glucocorticoid regulates interleukin-3 in systemic lupus erythematosus. J. Clin. Immunol. 2013, 33:111-117.
15. Luo Y., Cai X., Liu S., Wang S., Nold-Petry C.A., Nold M.F., et al. IL-37 suppresses contact hypersensitivity by inducing tolerogenic dendritic cells. Cytokine 2013, 63(3):283.
16. International Study Group for Behcet's Disease International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990, 335:1078-1080.
17. Touzot M., Cacoub P., Bodaghi B., Soumelis V., Saadoun D. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. Autoimmun. Rev. 2015, 14(5):370-375.
18. Cavuş F., Ulusoy C., Örçen A., Gül A., Tüzün E., Vural B. Increased IL-23 receptor, TNF-α and IL-6 expression in individuals with the IL23R-IL12RB2 locus polymorphism. Immunol. Lett. 2014, 160(1):96-98.
19. Ye Z., Wang C., Tang J., Zhou Y., Bai L., Liu Y., et al. Decreased interleukin-37 expression in Vogt-Koyanagi-Harada disease and upregulation following immunosuppressive treatment. J. Interferon Cytokine Res. 2015, 35(4):265-272.
20. Boraschi D., Lucchesi D., Hainzl S., Leitner M., Maier E., Mangelberger D., et al. IL-37, a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 2011, 22(3):127-147.
21. Ye Z., Wang C., Kijlstra A., Zhou X., Yang P. A possible role for interleukin 37 in the pathogenesis of Behcet's disease. Curr. Mol. Med. 2014, 14:535-542.
22. Hatemi G., Seyahi E., Fresko I., Hamuryudan V. Behçet's syndrome: a critical digest of the recent literature. Clin. Exp. Rheumatol. 2012, 30(3 Suppl. 72):S80-9.
23. Pay S., Simsek I., Erdem H., Pekel A., Musabak U., Sengul A., et al. Dendritic cell subsets and type I interferon system in Behçet's disease: does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization?. Clin. Exp. Rheumatol. 2007, 25(4 Suppl. 45):S34-40.
24. Wu W., Luo Y., Wang W, Yu G, Shen Y, Sun Z, et al. Interleukin-37 inhibits the activation of mouse dendritic cells induced by lipopolysaccharides]. Xi Bao Yu Fen ZiMian Yi XueZaZhi.(2015); 31(4):433-6.
25. Moretti S., Bozza S., Oikonomou V., Renga G., Casagrande A., Iannitti R.G., et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014, 10(11):e1004462.
26. Hamzaoui K., Hamzaoui A. Immunological responses in patients with Behçet's disease: advances in understanding. Expert Rev. Ophtalmol. 2012, 7(3):261-270.
27. Velhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFb in the context of an inflammatory cytokinemilieu supports de novo differentiation ofIL-17-producing T cells. Immunity 2006, 24:179-189.
28. Ye L., Jiang B., Deng J., Du J., Xiong W., Guan Y., et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J. Immunol. 2015, 194(11):5110-5119.
29. Bufler P., Gamboni-Robertson F., Azam T., Kim S.H., Dinarello C.A. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem. J. 2004, 381:503-510.
30. Li S., Neff C.P., Barber K., Hong J., Luo Y., Azam T., et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptorIL-1R8. Proc. Natl. Acad. Sci. U. S. A. 2015, 2497-2502.
31. Sakai N., Van S., weringen H.L., Belizaire R.M., Quillin R.C., Schuster R., Blanchard J., Burns J.M., Tevar A.D., Edwards M.J., Lentsch A.B. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J. Gastroenterol. Hepatol. 2012, 27(10):1609-1616.
32. Teng X., Hu Z., Wei X., Wang Z., Guan T., Liu N., et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J. Immunol. 2014, 192(4):1815-1823.
33. van de Veerdonk F.L., Gresnigt M.S., Oosting M., van der Meer J.W., Joosten L.A., Netea M.G., et al. Protective host defenseagainstdisseminatedcandidiasisisimpaired in miceexpressing human interleukin-37. Front. Microbiol. 2014, 5:762. 10.3389/fmicb.
34. Arida A., Sfikakis P.P. Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease. Clin. Exp. Rheumatol. 2014, 32(4 Suppl. 84):S149-55.
35. Calvo-Río V., Blanco R., Beltrán E., Sánchez-Bursón J., Mesquida M., Adán A., Hernandez M.V., et al. Anti-TNF-í therapy in patients with refractoryuveitis due to Beháet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014, 53(12):2223-2231.
36. Addimanda O., Pipitone N., Pazzola G., Salvarani C. Tocilizumab for severerefractoryneuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin. Arthritis Rheum. 2015, 44(4):472-475.